Washington, D.C. (February 28, 2002)-The Biotechnology Industry Organization (BIO) board of directors has by unanimous vote named Dennis M. Fenton, Ph.D., to their ranks. Fenton is executive vice president of Amgen, where he is responsible for operations, manufacturing, process development, quality and information management.
“We are very pleased to have Dennis, one of Amgen’s pioneer scientists, join our board of directors,” said BIO President Carl B. Feldbaum. “During critical negotiations for reauthorization of the Prescription Drug User Fee Act, it is especially timely for our 47-member board to have the experienced voice of one of the industry’s largest and best-known companies.
“The outcome of these negotiations will have an important impact on the drug approval process for years to come,” Feldbaum said, “and Dennis brings an experienced scientific perspective to the issue.”
In addition to his 20-year tenure at Amgen, Fenton spent several years at Pfizer Central Research in new product development. He is a member of the American Society for Microbiology, the Society for Industrial Microbiology, the American Chemical Society and the Parenteral Drug Association, and also serves on the board of directors of the National Health Foundation.
Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural and environmental biotechnology products.